Ali Taghizadeh, Associate Professor of Clinical Oncology at MUMS and Vice President of Omid Oncology Hospital, shared a post on LinkedIn:
“First Clinical Implementation of BM-Sparing IMRT in Prostate Cancer in Mashhad (MUMS).
The initial applications of bone marrow–sparing IMRT in prostate cancer were largely extrapolated from pelvic IMRT experiences in gynecologic and gastrointestinal malignancies, rather than derived from prostate-specific randomized trials.
Early adopters incorporated pelvic bone marrow as a secondary OAR during IMRT planning, without compromising target coverage or established rectal and bladder constraints.”
More posts about Prostate Cancer on OncoDaily.